Steven L. Hoerter - 15 Feb 2024 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc.

Role
President and CEO, Director
Signature
/s/ Jeffrey M. Held, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Feb 2024
Net transactions value
$0
Form type
4
Filing time
20 Feb 2024, 16:05:24 UTC
Previous filing
14 Dec 2023
Next filing
11 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $0 +298,100 $0.000000 298,100 15 Feb 2024 Common Stock 298,100 $15.92 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2024.